- Report
- March 2024
- 180 Pages
Global
From €3270EUR$3,374USD£2,801GBP
€3633EUR$3,749USD£3,112GBP
- Report
- November 2023
- 87 Pages
Global
From €5766EUR$5,950USD£4,939GBP
- Report
- April 2024
- 92 Pages
Global
From €5427EUR$5,600USD£4,648GBP
- Report
- March 2024
- 200 Pages
Global
From €4022EUR$4,150USD£3,445GBP
- Report
- March 2018
- 220 Pages
Global
From €2132EUR$2,200USD£1,826GBP
Diastat is a brand of central nervous system (CNS) drugs used to treat seizures. It is a form of diazepam, a benzodiazepine, and is administered rectally. Diastat is used to treat acute repetitive seizures, also known as status epilepticus, in patients aged 6 months and older. It is also used to treat cluster seizures in patients aged 5 years and older. Diastat is available in a variety of forms, including a gel, a liquid, and a rectal suppository.
The Diastat market is a subset of the larger CNS drugs market. CNS drugs are used to treat a variety of neurological conditions, including epilepsy, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The Diastat market is highly competitive, with a number of companies offering similar products.
Some of the companies in the Diastat market include Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, and Actavis. Show Less Read more
